The approval makes Cimzia the first Fc-free, PEGylated anti-TNF treatment option for this indication.
Most patients seen in primary care have mild to moderate plaque psoriasis, which is usually treatable with topical therapies.
This novel interleukin-23 inhibitor targets psoriatic inflammation.
Help your patients help themselves. Take a look at 6 rheumatology apps you can discuss at the next visit.
In late-breaking clinical trials, 3 novel biologic drugs show promise for the treatment of moderate to severe plaque psoriasis.
Another potential indication for medical marijuana: psoriasis.
The risk of dying as a result of alcohol-related causes is greater in persons who have the condition.
This study was the first to use an objective measure to link severity of psoriasis and risk of death.
A new noninvasive approach to assessment for patients receiving methotrexate therapy might reduce the number of liver biopsies.
Clinical trial shows that switching from the infliximab originator to its biosimilar does not compromise safety or effectiveness of treatment.